254 related articles for article (PubMed ID: 23193945)
1. Ultrasonographic markers and preoperative CA-125 to distinguish between borderline ovarian tumors and stage I ovarian cancer.
Zacharakis D; Thomakos N; Biliatis I; Rodolakis A; Simou M; Daskalakis G; Bamias A; Antsaklis A
Acta Obstet Gynecol Scand; 2013 Mar; 92(3):285-92. PubMed ID: 23193945
[TBL] [Abstract][Full Text] [Related]
2. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
[TBL] [Abstract][Full Text] [Related]
3. Is CA-125 an additional help to radiologic findings for differentiation borderline ovarian tumor from stage I carcinoma?
Lee EJ; Kim SH; Kim YH; Lee HJ
Acta Radiol; 2011 May; 52(4):458-62. PubMed ID: 21498310
[TBL] [Abstract][Full Text] [Related]
4. Differentiating between borderline and invasive malignancies in ovarian tumors using a multivariate logistic regression model.
Chen J; Chang C; Huang HC; Chung YC; Huang HJ; Liou WS; Chiang AJ; Teng NN
Taiwan J Obstet Gynecol; 2015 Aug; 54(4):398-402. PubMed ID: 26384058
[TBL] [Abstract][Full Text] [Related]
5. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
6. Plasma fibrinogen levels in patients with benign and malignant ovarian tumors.
Hefler-Frischmuth K; Lafleur J; Hefler L; Polterauer S; Seebacher V; Reinthaller A; Grimm C
Gynecol Oncol; 2015 Mar; 136(3):567-70. PubMed ID: 25576886
[TBL] [Abstract][Full Text] [Related]
7. Pre-operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound.
Arun-Muthuvel V; Jaya V
Asian Pac J Cancer Prev; 2014; 15(6):2929-32. PubMed ID: 24761927
[TBL] [Abstract][Full Text] [Related]
8. Plasma immune analytes in patients with epithelial ovarian cancer.
Block MS; Maurer MJ; Goergen K; Kalli KR; Erskine CL; Behrens MD; Oberg AL; Knutson KL
Cytokine; 2015 May; 73(1):108-13. PubMed ID: 25743245
[TBL] [Abstract][Full Text] [Related]
9. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.
Stiekema A; Lok CA; Kenter GG; van Driel WJ; Vincent AD; Korse CM
Gynecol Oncol; 2014 Mar; 132(3):573-7. PubMed ID: 24418200
[TBL] [Abstract][Full Text] [Related]
10. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors.
Alanbay I; Aktürk E; Coksuer H; Ercan CM; Karaşahin E; Dede M; Yenen MC; Ozan H; Dilek S
Eur J Gynaecol Oncol; 2012; 33(1):25-30. PubMed ID: 22439401
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
12. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis.
Luo Y; Kim HS; Kim M; Lee M; Song YS
J Gynecol Oncol; 2017 May; 28(3):e36. PubMed ID: 28382799
[TBL] [Abstract][Full Text] [Related]
13. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors).
Gundogdu F; Soylu F; Erkan L; Tatli O; Mavi S; Yavuzcan A
Arch Gynecol Obstet; 2011 Jun; 283(6):1397-402. PubMed ID: 20645105
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors.
Zhang S; Yu S; Hou W; Li X; Ning C; Wu Y; Zhang F; Jiao YF; Lee LTO; Sun L
J Ovarian Res; 2019 Sep; 12(1):87. PubMed ID: 31526390
[TBL] [Abstract][Full Text] [Related]
16. The serum CA-125 concentration data assists in evaluating CT imaging information when used to differentiate borderline ovarian tumor from malignant epithelial ovarian tumors.
Shin JE; Choi HJ; Kim MH; Cho KS
Korean J Radiol; 2011; 12(4):456-62. PubMed ID: 21852906
[TBL] [Abstract][Full Text] [Related]
17. New sonographic marker of borderline ovarian tumor: microcystic pattern of papillae and solid components.
Timor-Tritsch IE; Foley CE; Brandon C; Yoon E; Ciaffarrano J; Monteagudo A; Mittal K; Boyd L
Ultrasound Obstet Gynecol; 2019 Sep; 54(3):395-402. PubMed ID: 30950132
[TBL] [Abstract][Full Text] [Related]
18. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer.
Manganaro L; Michienzi S; Vinci V; Falzarano R; Saldari M; Granato T; Viggiani V; Frati L; Anastasi E
Oncol Rep; 2013 Nov; 30(5):2481-7. PubMed ID: 23970060
[TBL] [Abstract][Full Text] [Related]
19. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
